Brokers Issue Forecasts for Codexis FY2025 Earnings

Codexis, Inc. (NASDAQ:CDXS) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for Codexis in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biotechnology company will post earnings of ($0.51) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $11.00 price objective on the stock. The consensus estimate for Codexis’ current full-year earnings is ($0.77) per share.

Separately, Benchmark reiterated a “hold” rating on shares of Codexis in a research note on Monday, November 4th.

Codexis Price Performance

Shares of CDXS opened at $4.91 on Thursday. Codexis has a twelve month low of $2.53 and a twelve month high of $6.08. The company has a market capitalization of $399.58 million, a P/E ratio of -5.64 and a beta of 2.13. The firm has a 50 day moving average of $4.90 and a 200 day moving average of $3.80. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). The firm had revenue of $12.83 million during the quarter, compared to the consensus estimate of $11.64 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. During the same quarter in the previous year, the firm earned ($0.26) EPS.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. FMR LLC raised its stake in Codexis by 1.2% during the 3rd quarter. FMR LLC now owns 4,497,090 shares of the biotechnology company’s stock valued at $13,851,000 after buying an additional 51,822 shares during the last quarter. Geode Capital Management LLC increased its position in Codexis by 0.7% during the third quarter. Geode Capital Management LLC now owns 1,644,039 shares of the biotechnology company’s stock valued at $5,065,000 after acquiring an additional 11,082 shares during the last quarter. State Street Corp increased its position in Codexis by 2.7% during the third quarter. State Street Corp now owns 1,551,411 shares of the biotechnology company’s stock valued at $4,778,000 after acquiring an additional 41,480 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in Codexis by 23.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,103,442 shares of the biotechnology company’s stock valued at $3,399,000 after acquiring an additional 209,207 shares during the period. Finally, abrdn plc boosted its position in Codexis by 62.5% in the third quarter. abrdn plc now owns 800,410 shares of the biotechnology company’s stock worth $2,465,000 after purchasing an additional 307,762 shares during the last quarter. 78.54% of the stock is owned by hedge funds and other institutional investors.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.